Novartis’ Remibrutinib Demonstrates Strong Phase III Efficacy in Chronic Inducible Urticaria

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1 Remibrutinib, a hi...

February 19, 2026 | Thursday | News
Andelyn Biosciences Expands Commitment to Rare Disease Community with NKH Gene Therapy Manufacturing Program

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selecte...

February 19, 2026 | Thursday | News
Worldwide Clinical Trials Completes Catalyst Clinical Research Acquisition to Expand Oncology and Global CRO Capabilities

CRO expands oncology, adds functional service provider capabilities, strengthens global reach, and accelerates technology to enhance customer value ...

February 18, 2026 | Wednesday | News
QuidelOrtho Strengthens Global Immunoassay Portfolio Through Strategic Agreement With Lifotronic Technology

QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 68838...

February 17, 2026 | Tuesday | News
Alto Neuroscience, Inc. Completes Patient Enrollment in Phase 2 Trial of ALTO-101 for Schizophrenia-Related Cognitive Impairment

-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...

February 16, 2026 | Monday | News
Valar Labs Expands AI Oncology Platform with Vitara Pancreas ChemoPredict Validation

New AI diagnostic, Vitara Pancreas ChemoPredict, can select optimal first-line treatment for advanced pancreatic cancer patients. Valar Labs, ...

February 13, 2026 | Friday | News
Novocure Advances Pancreatic Cancer Care with FDA Approval of Optune Pax®

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic...

February 13, 2026 | Friday | News
Agilent PD L1 IHC 22C3 PharmDx Secures FDA Approval To Guide KEYTRUDA In Ovarian Cancer

Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. announced ...

February 13, 2026 | Friday | News
Ferronova Completes Patient Enrolment in Pivotal Trial of FerroTrace Surgical Imaging Technology

Australian company Ferronova announced it has completed enrolment of patients for its two-year trial to progress commercialisation of FerroTrace, a ...

February 11, 2026 | Wednesday | News
MerryLife Advances Multi-Pathway Alzheimer’s Therapy TML-6 Following Positive Phase 1 Data

MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, announced positive Phase 1 results for TML-6, it...

February 11, 2026 | Wednesday | News
Bristol Myers Squibb Partners with Evinova to Advance AI Driven Clinical Trial Optimization

Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency ...

February 10, 2026 | Tuesday | News
Peijia Medical Advances Global Expansion with EU MDR CE Mark Filing for GeminiOne TEER System

Peijia Medical Limited announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application fo...

February 10, 2026 | Tuesday | News
Genentech Advances Regulatory Path for Fenebrutinib After Phase III Success in Progressive MS

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority co...

February 09, 2026 | Monday | News
Ascentage Pharma Strengthens Hematologic Cancer Pipeline with Global Clinical Advancement of APG-3288

Ascentage Pharma Group International , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commerc...

February 09, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close